Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up to $25.46

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $25.46, but opened at $26.44. Dyne Therapeutics shares last traded at $25.51, with a volume of 33,728 shares.

Analyst Ratings Changes

DYN has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, March 6th. Piper Sandler boosted their price target on Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Chardan Capital boosted their price target on Dyne Therapeutics from $20.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, March 8th. Stifel Nicolaus boosted their price target on Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Finally, Raymond James boosted their price target on Dyne Therapeutics from $27.00 to $56.00 and gave the company a “strong-buy” rating in a research note on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.75.

Dyne Therapeutics Trading Up 2.1 %

The firm has a fifty day simple moving average of $26.21 and a 200-day simple moving average of $18.18.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.17). Equities analysts expect that Dyne Therapeutics, Inc. will post -3.25 earnings per share for the current year.

Insider Activity

In other news, insider Wildon Farwell sold 1,585 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $25.70, for a total value of $40,734.50. Following the transaction, the insider now owns 151,590 shares of the company’s stock, valued at approximately $3,895,863. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Wildon Farwell sold 1,585 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $25.70, for a total value of $40,734.50. Following the completion of the sale, the insider now owns 151,590 shares in the company, valued at approximately $3,895,863. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Jason P. Rhodes sold 248,219 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $23.72, for a total transaction of $5,887,754.68. Following the completion of the sale, the director now owns 903,527 shares of the company’s stock, valued at approximately $21,431,660.44. The disclosure for this sale can be found here. Insiders have sold a total of 1,875,432 shares of company stock valued at $44,368,530 in the last 90 days. 20.77% of the stock is owned by company insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Capstone Investment Advisors LLC bought a new position in Dyne Therapeutics during the 1st quarter worth about $575,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Dyne Therapeutics by 24.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,617 shares of the company’s stock worth $812,000 after buying an additional 5,696 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Dyne Therapeutics by 5.9% during the 1st quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock worth $437,000 after buying an additional 857 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Dyne Therapeutics by 119.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,573 shares of the company’s stock worth $442,000 after buying an additional 8,474 shares during the last quarter. Finally, Wetzel Investment Advisors Inc. acquired a new position in shares of Dyne Therapeutics during the 1st quarter worth about $28,000. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.